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Death receptors, such as Fas and tumor necrosis fac-
tor-related apoptosis-inducing ligand receptors, recruit
Fas-associated death domain and pro-caspase-8 ho-
modimers, which are then autoproteolytically activated.
Active caspase-8 is released into the cytoplasm, where it
cleaves various proteins including pro-caspase-3, result-
ing in apoptosis. The cellular Fas-associated death do-
main-like interleukin-1--converting enzyme-inhibitory
protein long form (FLIPL), a structural homologue of
caspase-8 lacking caspase activity because of several
mutations in the active site, is a potent inhibitor of
death receptor-induced apoptosis. FLIPL is proposed to
block caspase-8 activity by forming a proteolytically in-
active heterodimer with caspase-8. In contrast, we pro-
pose that FLIPL-bound caspase-8 is an active protease.
Upon heterocomplex formation, a limited caspase-8 au-
toprocessing occurs resulting in the generation of the
p43/41 and the p12 subunits. This partially processed
form but also the non-cleaved FLIPL-caspase-8 hetero-
complex are proteolytically active because they both
bind synthetic substrates efficiently. Moreover, FLIPL
expression favors receptor-interacting kinase (RIP)
processing within the Fas-signaling complex. We pro-
pose that FLIPL inhibits caspase-8 release-dependent
pro-apoptotic signals, whereas the single, membrane-
restricted active site of the FLIPL-caspase-8 heterocom-
plex is proteolytically active and acts on local substrates
such as RIP.
Apoptosis is a vital mechanism in multicellular organisms to
eliminate unwanted cells during development, tissue homeo-
stasis, and immune system function (1). Initiation and regula-
tion of apoptosis is highly controlled through specific protein-
protein interactions and by a family of proteolytic enzymes, the
caspases (2, 3). One way to induce apoptosis is via death recep-
tors, a subgroup of the tumor necrosis factor receptor super-
family (4). The death signal is transmitted through the binding
of extracellular death ligands such as the Fas ligand (FasL)1 to
its receptor Fas resulting in conformational changes of pre-
formed receptor clusters (5). Intracellularly this change leads
to the recruitment of the adaptor protein FADD (6, 7) and of the
initiator caspases, caspase-8 and -10 (8, 9). Fas and FADD
interact via homophilic death domain interactions, whereas
FADD and the pro-caspases interact through death effector
domains (DED). Ligand, receptor, adaptor protein, and
caspases form the death inducing signaling complex (DISC)
(10). When recruited to the DISC, pro-caspase-8 or -10 is acti-
vated through a series of proteolytic cleavage steps. Activation
of pro-caspases generally involves the cleavage within the pro-
teolytic caspase domain, resulting in active caspase comprising
a large () and small () subunit, as well as the removal of the
N-terminal domain.
Apoptosis by death receptors is regulated at different levels
of the signaling pathway. The viral caspase inhibitors CrmA
and p35 block caspase-8 once it is activated and released from
the membrane-bound DISC (11). FLIP is a potent inhibitor of
death receptor-mediated pro-apoptotic signals, blocking the
signaling pathway more upstream, before caspase-8 activation
and release (12–19). Two forms, FLIPL (long form) and FLIPS
(short form) have been characterized so far (20, 21), which
correspond to FLIP splice variants at the mRNA level. FLIPS
consists of two DEDs, whereas FLIPL has an additional
C-terminal caspase domain and resembles caspase-8 in its
overall structural organization. In the protease-like domain of
FLIPL the catalytically active cysteine is replaced by a tyrosine
rendering the molecule proteolytically inactive (20, 21).
Pro-caspase-8 and FLIPL are recruited to the DISC, where
both molecules are partly processed and the cleaved interme-
diates remain bound to the DISC (12, 22). In a recent paper,
Krueger et al. (23) demonstrated that FLIPL but not FLIPS or
a mutant lacking the small subunit of the protease domain
contributes to the first cleavage step of caspase-8. It is assumed
that, in both cases, caspase-8 activity is highly impaired, ren-
dering cells resistant to death receptor-induced apoptosis (24).
The precise physiological role of FLIP is still debated. Anal-
ysis of FLIP-deficient mice revealed not only its importance in
the regulation of death receptor-induced apoptosis, but also in
embryonic development (25). Cells deficient for FLIP are more
susceptible to death receptor-mediated apoptosis (26), and this
anti-apoptotic activity of FLIP is likely to control T cell survival
(12). Moreover, high levels of FLIP lead to increased sensitivity
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of T cells toward T cell receptor stimulation and result in
increased synthesis of interleukin-2, probably as a result of the
capacity of FLIP to activate the NF-B and c-Jun N-terminal
kinase signaling pathways (27, 28). These latter activities may
also contribute to its effect on tumor growth (29, 30).
However, proapoptotic activities of FLIPL have also been
described. Overexpression of FLIP in HEK 293T cells was
reported by several groups to cause efficient cell death (15–19).
The reason for this cytocidal effect of FLIPL is presently
unclear.
In this report, the pro-apoptotic activity of FLIPL was inves-
tigated in more detail. We demonstrate that FLIPL promotes
the first proteolytic cleavage of pro-caspase-8 but prevents
further cleavage of caspase-8. Caspase-8, when bound to
FLIPL, shows proteolytic activity. We propose that FLIPL in-
teracts with pro-caspase-8 through the DEDs and the protease
domains. The existence of FLIPL-pro-caspase-8 heterodimers
can explain the observed sequence of events at the DISC.
Through association of the protease domains, FLIPL activates
pro-caspase-8 differently compared with activation in a ho-
modimer, resulting in a partially active protease restricted to
the cell membrane. The consequences for cells are the inter-
ruption of the apoptotic pathway and the presence of a proteo-
lytic complex, which may act on substrates localized at the
DISC such as RIP.
EXPERIMENTAL PROCEDURES
Cell Culture—The 293T human embryonic kidney cell line were
cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% fetal calf serum and penicillin/streptomycin (100
g/ml of each) and grown in 5% CO2 at 37 °C. Raji cells (Burkitt’s
lymphoma B cell lines) were cultured in RPMI 1640 containing 10%
fetal calf serum and penicillin/streptomycin. Raji clones expressing
FLIPs, FLIPL, or mock transfected were obtained and cultured as pre-
viously described (12).
Reagents—Soluble recombinant human soluble FLAG-FasL, Super-
FasL, rat mAb anti-cFLIP (Dave II), and zVAD-fmk was purchased
from Apotech Co. (San Diego, CA). Biotin-DEVD-aomk (L772,094) was
a kind gift from Donald W. Nicholson (Merck Frosst Centre for Thera-
peutic Research, Quebec, Canada). Anti-FLAG (M2) antibody was from
Sigma. Rabbit polyclonal anti-TRAF2 (C20) and anti-Fas (C20) were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse
mAb anti-RIP and anti-FADD were from Transduction Laboratories
(Lexington, KY). Mouse mAb mouse anti-caspase-8 (IgG2b) was from
MBL (Nagoya, Japan).
DISC Analysis—Raji cells were grown to densities between 1 and 2
106 cells/ml in roller bottles, and 5  107 cells/ml were treated with
FasL (2 g/ml) in the presence or absence of cross-linking anti-FLAG (2
g/ml) for the indicated times. Cells were rapidly cooled by adding five
volumes of ice-cold phosphate-buffered saline, lysed with 0.2% Nonidet
P-40, Tris-HCl (20 mM, pH 7.4), NaCl (150 mM), 10% glycerol, and the
protease inhibitor mixture (Roche Molecular Biochemicals). Cytosolic
fractions were precleared with Sepharose 6B (Sigma-Aldrich) for 60
min and then incubated with protein G-coupled Sepharose beads
(Amersham Biosciences) for 3 h. Beads were washed four times with
lysis buffer. Proteins were resolved by SDS-PAGE and blotted onto
nitrocellulose membranes. Blocked in phosphate-buffered saline con-
taining 0.5% Tween 20 and 5% (w/v) dry milk, membranes were subse-
quently incubated with specific primary antibodies and revealed using
horseradish peroxidase-conjugated goat anti-rabbit IgG, goat anti-rat
IgG or goat anti-mouse (Jackson Immunoresearch Laboratories, West
Grove, PA) and ECL (Amersham Biosciences). Mouse monoclonal anti-
bodies were specifically revealed by use of horseradish peroxidase-
conjugated goat anti-mouse IgG1, IgG2a, and IgG2b from Southern
Biotechnology Associates (Birmingham, AL).
Receptor-induced Signaling Complex (RISC)—Immunoprecipitation
of the signaling complex associated to Fas receptor was performed
taking advantage of the VSV-tagged version of FLIP (short or long) in
the Raji clones. Briefly, cells were stimulated with Super-FasL (Apo-
tech, www.apotech.com) for the indicated times and analyzed as de-
scribed above, but immunoprecipitation was performed using an anti-
VSV antibody.
Biotinylation of Caspase-8—Biotinylation of catalytically active
caspase-8 associated to Fas receptor or FLIP was performed as follows.
Lysates of the various Raji clones stimulated with Fas ligand were
incubated with 5 M biotin-DEVD-aomk for 30 min at 37 °C and sub-
sequently processed for DISC or RISC analysis as described above,
except that streptavidin beads were used for immunoprecipitation.
Biotin-modified proteins were visualized by Western blot using strepta-
vidin coupled to horseradish peroxidase.
Sequence Alignment—Crystal structures available in the PDB data
bank (31) for caspase-1 (1BMQ (Ref. 32), 1IBC (Ref. 33), 1ICE (Ref. 34)),
caspase-3 (1CP3 (Ref. 35), 1PAU (Ref. 36), 1GFW (Ref. 37)), capase-7
(1GQF (Ref. 38), 1F1J (Ref. 39), 1I4O (40), 1I51 (Ref. 41), 1K86 (Ref. 42),
1K88 (Ref. 42), 1KMC (Ref. 38)), caspase-8 (1QDU (Ref. 43), 1QTN (Ref.
44), 1F9E (Ref. 45)), and caspase-9 (1JXQ (Ref. 46)) were used for
structural alignment in the following way; all / heterodimers were
superimposed using the six-dimensional search algorithm implemented
in the program Superimpose (47). Taking the C positions of the
caspase-8 structure as a reference C position, differences were calcu-
lated using the program Strupro (O related program) between corre-
sponding residues of the template and each superimposed  het-
erodimer. Amino acids, for which the C distance was less than 3.5 Å,
were defined as structurally aligned residues (48). The sequence of
c-FLIPL was then aligned to this structure-based sequence alignment
template using ClustalX (49). Manual corrections were applied to align
deletions and insertions of FLIPL with insertion and deletion regions in
the template.
Model Building—Model structures for the FLIPL heterodimer were
created using all available heterodimer structures (Modeler (Ref. 50))
and the alignment described above. Model structures for the heterotet-
rameric / caspase-8-FLIPL were calculated using the structure of
caspase-9 (46) as a template. Model structures of the heterotetrameric
/ pro-caspase-8-FLIPL were computed using the structure of
caspase-7 (38) as a template. Each model was checked with Procheck
(CCP4 program suite (Ref. 51)) using a resolution of 3.0 Å. In each case
the model with the best stereochemistry was chosen for further
analysis.
Calculation of Shape Surface Complementarity—The shape surface
complementarity of the  interfaces of both the heterotetramer pro-
caspase-8-FLIPL and caspase-8-FLIPL was calculated using the pro-
gram SC from CCP4 (52). The probe sphere used to define the solvent-
excluded surface was set to 1.7 Å. A peripheral band of 1.5 Å that is a
part of the buried portion of the molecular surface was omitted from the
calculation. A weighting factor of 0.5 Å2 was used in the calculation of
the surface complementarity (52, 53). Surfaces were visualized using
GRASP (54). The color ramp used in GRASP was defined as blue for a
SC value of 1 going to white for a SC value of 0. Interfaces colored in
blue match precisely, whereas white interface areas are not correlated.
Non-interacting surfaces are colored in red.
Calculation of Electrostatic Surface Complementarity—Surface elec-
trostatics were calculated using the program GRASP (54) applying
charges files (full.crg and back_no_h.crg) and radii file (default.siz). The
inner dielectric constant was set to 4.0 and the bulk salt concentration
to 0.145 (55).
The electrostatic surface complementarity is illustrated by coloring
the surface of both interacting subunits. Regions where the colors are
opposite (blue-red for complementarity) match, whereas identical colors
indicate electrostatic clashes. For simplicity the surface color of one
interaction partner was projected onto the other. The desolvation po-
tential and the bound-state potential were calculated as described by
Kangas et al. (55).
Calculation of r.m.s.d. Values—r.m.s.d. values were calculated using
the command lsq_explicit from the program O (56) for C positions. For
this analysis, residues 322–334, 338–341, 347–360, 365–374, 387–389,
and 393–401, which form the secondary structure elements in caspases
(numbering from coordinate structure 1ICE (34) were used to define the
central core of the  subunit. The r.m.s.d. values of the  core in the
pro-caspase-8-FLIPL and the caspase-8-FLIPL model were calculated
using the  core of caspase-8-caspase-8 as a template (PDB file 1F9E
(Ref. 45)). As a negative control, the r.m.s.d. of the  core in a caspase-
3-FLIPL model was also calculated using the  core of caspase-3 as a
template (PDB file 1CP3 (Ref. 43)).
RESULTS
In agreement with several previous reports (12, 14–19), we
found that FLIPL, when overexpressed at high levels in 293T
human embryonic kidney cells, did not protect cells from apo-
ptosis but efficiently caused cell death in a ligand-independent
manner (Fig. 1A). In contrast to FLIPL, FLIPS caused little or
no cell death (Fig. 1A). FLIPL-induced cell death was inhibited
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by zVAD-fmk and Ile-Glu-Thr-Asp-fluoromethylketone (Fig. 1
and data not shown), suggesting that FLIPL can induce apo-
ptosis via activation of caspase-8. We therefore analyzed
whether caspase-8 activation differed in cells expressing either
FLIPL or FLIPS. Caspase-8 was indeed partially processed in
cells overexpressing FLIPL, whereas, in cells harboring the
small form, primarily the precursor caspase-8 was detectable
(Fig. 1B). FLIPL-induced caspase-8 processing was dose-
dependent and became apparent when cDNA doses of FLIP
used for transfection were high (data not shown). Activation of
caspase-8 is thought to occur in a two-step mechanism. The
initial cleavage occurs after Asp-374 (Asp-299 using 1ICE num-
bering (Ref. 34)), giving raise to the p43/p41 and the p12 sub-
units, whereas, in a second step, cleavage occurs after Asp-216
and Asp-384 (Asp-143 and Asp-309 in 1ICE numbering), gen-
erating the p18 () and p10 () subunits of the active enzyme
(11). Interestingly, FLIPL-induced caspase-8 processing was
limited to the first step, as further processing of the p43/p41
fragment was not observed. This suggested that processing
between the large and small subunit suffices to expose the
caspase-8 active site.
We next decided to investigate whether, upon Fas stimula-
tion, partial caspase-8 processing also occurs in cells overex-
pressing FLIPL and whether the FLIP-bound activated
caspase-8 exhibited proteolytic activity. To this end, DISC for-
mation was analyzed in Raji B cells stably transfected with
either FLIPL or FLIPS (Fig. 2). Recombinant, FLAG-tagged
FasL was added to Raji cells and anti-FLAG immunoprecipi-
tates analyzed after various periods of time. Rapid recruitment
of FADD, RIP, caspase-8, and FLIP to the engaged receptor
was observed (Figs. 2 and 5). In cells overexpressing FLIPL,
partial cleavage of caspase-8 in the DISC was most rapid. By 5
min after the addition of FasL, complete conversion of the
caspase-8 precursor form into the p43/p41 partially processed
form was detected in the DISC, whereas, in the cytoplasmic
caspase-8 pool, no processing of caspase-8 was noticeable even
1 h after ligand addition. In contrast, in cells expressing FLIPS,
most of the caspase-8 remained in the precursor form at the
level of the DISC and in the cytoplasm, in accord with a pre-
vious report using BJAB B lymphoid cell (23). The p43/p41
band was also detectable in wild-type Raji cells despite the fact
that wild-type Raji cells did not express detectable FLIPL in
cell extracts (Fig. 2). However, closer examination revealed
that endogenous processed FLIPL was enriched at the level of
the DISC, which may explain the presence of partially pro-
cessed caspase-8. Thus, caspase-8 processing is rapid and effi-
cient in the presence of FLIPL but not FLIPS, indicating that
the caspase-8 moiety of FLIP is required to promote partial
caspase-8 processing.
If a direct interaction between FLIPL and caspase-8 induces
processing of caspase-8, predominantly processed caspase-8
should be found in association with FLIPL but not with FLIPS.
To test this prediction, we analyzed caspase-8 association with
FLIP during DISC formation, by immunoprecipitating FLIP
using antibodies recognizing the VSV-tagged transfected FLIP.
In a FasL stimulation-dependent manner, FLIP immunopre-
cipitates contained caspase-8, FADD, and Fas (Fig. 3). A large
FIG. 1. FLIPL induces apoptosis in 293T cells. A, 293T cells were
transfected with 5 g of plasmid coding for FLIPL and FLIPS, respec-
tively (control, mock). Cells were analyzed by confocal microscopy. The
arrow points to rounded, typically apoptotic cells. B, cell extracts were
analyzed by Western blot analysis for the expression of transfected
FLIPL using an -FLIP antibody and for processing of endogenous
caspase-8 (-Casp-8). Note that the inhibitor zVAD-fmk does not effi-
ciently block caspase-8 processing.
FIG. 2. FLIPL induces processing of caspase-8. Western blot of
lysates (CE) and DISCs (IP) of Raji cells stably transfected with empty
vector (mock), VSV-FLIPL, or VSV-FLIPS. Cells were stimulated for
various time periods with FLAG-tagged FasL, which, after detergent
lysis, was subsequently immunoprecipitated using the anti-FLAG M2
antibody. In time point 0, the FasL was added after lysis. The extracts
and the DISC were analyzed for the presence of Fas, FADD, caspase-8,
and FLIP using the respective antibodies. Fas* refers to a high molec-
ular mass species of Fas, which occurs upon FasL engagement.
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portion of the co-precipitated Fas migrated with a molecular
mass of120 kDa. This modified form of Fas, which most likely
corresponds to aggregated Fas (10), is exclusively seen upon
Fas engagement (see also Fig. 2). All caspase-8 associated with
FLIPL was partially autoprocessed. In contrast, mostly pro-
caspase-8 was found in FLIPS immunoprecipitates, suggesting
that the conformational changes required for partial processing
of caspase-8 are dependent on the caspase-like domain of FLIP.
It has been previously proposed that FLIP inhibited cell
death by blocking the proteolytic activity of caspase-8 (24).
However, this is incompatible with the observation that FLIPL
undergoes a caspase-8-dependent rapid processing between the
large () and small () subunit of the caspase domain at
Asp-376 (Asp-299 in 1ICE numbering; see Figs. 1–3), resulting
in the generation of the 43- and 12-kDa fragments. Because
FLIP is proteolytically inactive, processing of FLIPL most likely
occurs through an adjacent caspase-8.
To get more direct evidence for the enzymatic activity of
FLIP-bound caspase-8, DISC-associated caspase-8 was ana-
lyzed for its capacity to interact with the biotinylated inhibitor
DEVD-aomk (57). Although this inhibitor was originally de-
signed for caspase-3, it blocks the activity of most caspases at
higher concentrations.2 This active-site probe requires cata-
lytic turnover to covalently biotinylate the active site cysteine.
The DISC was isolated in the presence of the biotinylated
inhibitor and incorporation examined by Western blot analysis
using streptavidin (Fig. 4). Two molecular species were found
to be biotinylated, which corresponded in size to precursor
caspase-8 a/b and to its p43/p41 partially cleaved forms (Fig.
4A). Interestingly, the presence of the caspase inhibitor during
the lysis procedure significantly blocked processing resulting in
an almost complete absence of the p43/p41 species. Although
FLIP cleavage was reduced it was not completely abolished
(Fig. 4A), suggesting that even precursor caspase-8 must have
some proteolytic activity, in accord with the observation that
the pro-form incorporates biotinylated substrate.
Inhibition of caspase-8 autoprocessing and biotinylation of
the zymogen form of caspase-8 was also observed when the
DISC was immunoprecipitated via FLIP (Fig. 4B). Surpris-
ingly, some caspase-8 association to FLIP was found to occur
already at time 0, which is in contrast to the experiments
shown in Fig. 3. As the only experimental difference was the
presence of caspase inhibitors, we repeated the experiments in
the presence of two other caspase inhibitors, i.e. zVAD-fmk and
biotin-zVAD-fmk. Again, FLIP-bound caspase-8 was seen with-
out prior FasL stimulation (Fig. 4C), suggesting that binding of
the inhibitor promotes association. This suggests a model in
which, upon caspase-8 binding to FLIPL, non-cleaved caspase-82 D. Nicholson, unpublished observation.
FIG. 5. The caspase-8-FLIPL but not the caspase-8-FLIPS het-
eromer induces cleavage of DISC-bound RIP. DISC analysis is
shown as described in Fig. 2. Note the appearance of cleaved RIP
(RIPp45) in cells with high levels of FLIPL. Abbreviations are as in
Fig. 2.
FIG. 3. FLIPL is associated primarily with processed
caspase-8. Cells were stimulated with FLAG-tagged RISCs as in Fig.
2. Following cell lysis, VSV-tagged FLIP proteins were immunoprecipi-
tated (IP) with an -VSV antibody and the associated complex was
analyzed by Western blot (WB). The filled arrowhead refers to a non-
specific band. In time 0, FasL was added after detergent lysis.
FIG. 4. Non-processed and processed caspase-8 are proteolyti-
cally active. A, DISC analysis of VSV-FLIPL-transfected Raji cells
using FasL to immunoprecipitate (IP) the complex. After cell lysis,
extracts were treated with biotin-DEVD-aomk and subsequently ana-
lyzed by Western blotting (WB) using antibodies to caspase-8 or strepta-
vidin to detect the covalently linked caspase inhibitor. B, VSV-FLIPL
and VSV-FLIPS-transfected Raji cells were treated as in A. FLIP was
immunoprecipitated with -VSV antibodies, and associated proteins
analyzed by Western blot analysis. C, FLIP-associated proteins were
analyzed without prior addition of FasL in the presence or absence of
the indicated caspase inhibitors.
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FIG. 6. The pro-form of cellular FLIPL (FLIPL). A, structure based sequence alignment of FLIPL with caspase-1, -3, -7, -8, and -9. Caspase-1,
-3, -7, -8, and -9, labeled PDBhcasp1, PDBhcasp3, PDBhcasp7, PDBhcasp8, and PDBhcasp9, respectively, are aligned with FLIPL (labeled c-FLIPL,
SwissProt O15519) and pro-caspase-8 (labeled hCasp8, SwissProt Q14790). B, stereo view of the superposition of caspase-8 (in red) with FLIPL (in
green). In FLIPL, loop-1 is missing and the activation loop has the same conformation as the one observed in caspase-7 (38) and in the inactive
subunit of caspase-9 (46). The picture was drawn using Setor (67) after superposition of caspase-8 (45) and FLIPL with Superimpose (47).
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zymogen undergoes a conformational rearrangement, thereby
acquiring catalytic competency. Binding of the inhibitor then
stabilizes this interaction and blocks autoprocessing.
We wondered whether the single active site present in the
FLIPL-caspase-8 heterodimer bound in the DISC would locally
cleave substrates other than FLIP. We reasoned that the most
likely candidates were proteins sterically close to FLIPL-
caspase-8, i.e. components of the DISC such as Fas, FADD, and
RIP. Indeed, a rapid processing of the kinase RIP was detect-
able (Fig. 5). A fragment of 38 kDa in size was detected imme-
diately after RIP recruitment to Fas in cells expressing FLIPL.
This corresponds in size to the fragment previously reported to
be generated through caspase-8 (Refs. 58 and 59 and data not
shown). Cleavage occurs at a typical caspase-8 site (LQLD324)
and separates the kinase domain from the death domain. Proc-
essing was considerably reduced in cells overexpressing FLIPS,
indicating that the caspase-like domain of FLIP promotes the
cleavage. Moreover, RIP processing was not observed in the
cytoplasm, demonstrating that RIP cleavage occurs at the level
of the DISC and is not caused by caspase-8 released into the
cytoplasm.
The above results suggested that a heterodimeric FLIPL-
caspase-8 complex can form in the DISC displaying enzymatic
activity, which does not, however, cause apoptosis. This com-
plex is quite unique, because the described functional caspases
are all thought to be homodimers. To strengthen this evidence
for the existence of FLIPL-caspase-8 heterodimers, a three-
dimensional model of the caspase-like domain of FLIPL was
constructed, based on the alignment and on the three-dimen-
sional structures of caspase-8, -1, -3, -6, and -7 (Fig. 6A). The
resulting FLIPL model (Fig. 6B) did not contain any bad con-
tacts in the / interface and exhibited a good geometry and
electrostatic complementarity. The high quality contacts in the
/ interface are supportive for a caspase-like fold of FLIPL.
Two c-FLIPL-caspase-8 heterodimer models were subse-
quently created (Fig 7A). The pro-caspase-8-FLIPL model was
based on the structure of pro-caspase-7 (38), and the caspase-
8-FLIPL model was based on the structure of caspase-9 (46) as
a template. For both models the caspase-8-FLIPL interfaces
were analyzed. Only small rearrangements in caspase-8 were
needed to accommodate a FLIPL molecule (Table I).
Analysis of the interface formed between (pro-)caspase-8 and
FIG. 7. Models of caspase-8-cFLIPL
hybrid molecules. A, model of pro-
caspase-8-FLIPL. Pro-caspase-8 (left) in-
teracts mainly via - contacts with
FLIPL (right). The activation loop, shown
in red, keeps the active site of pro-
caspase-8 in an inactive conformation.
Notably, Arg-413 (purple), which is part
of the S1 specificity pocket for the P1 Asp
residue of the substrate, is kept remote
from the active site. p18 subunits (dark
gray), p12 subunits (light gray), and
caspase-8 active site Cys (yellow, space-
filling representation) are also shown.
The shape complementarity (in blue for
high shape complementarity and white
for low shape complementarity) of the in-
terface is comparable with that observed
in the interface in the pro-caspase-7
structure (38). B, model of caspase-8-
FLIPL. In the caspase-8-FLIPL model, the
caspase-8 active site adopts the same con-
formation as the one observed in the in-
hibited structure of caspase-8 (45). The
activation loop is rearranged to create a
functional active site that can accommo-
date the P1 Asp residue of the substrate
(green). The shape complementarity of the
interface is comparable with that ob-
served in the interface in caspase-9 (46).
Small cavities (red) are visible in the
caspase-9 interface. The shape comple-
mentarity is very similar to the one ob-
served in the caspase-8 interface (45). In
contrast, low shape complementarity is
observed in a control model showing the
interface of a non-physiological caspase-8-
caspase-3 hybrid molecule. C, electro-
static complementarity in the caspase-
8-FLIPL model. The electrostatic
complementarity (blue for positively
charged areas and red for negatively
charged areas) at the interface between
caspase-8 and FLIPL is displayed. On the
left side the caspase-8 surface is shown
with the FLIPL interaction potential pro-
jected onto it. On the right side the sur-
face potential of caspase-8 is displayed.
Both interfaces are compatible. Pictures
were drawn using Setor (67).
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FLIPL revealed good shape complementary surfaces (Fig. 7, A
and B). The shape complementarity of the caspase-8-FLIPL
model was similar to that of pro-caspase-7 (38) (60 and 62%,
respectively). It revealed a value of 71%, similar to that ob-
served for the structure of pro-caspase-9 (46) (73%) and of the
inhibited caspase-8 (45) (72%) (Fig. 7B). This means that the
rearrangement of the caspase-8 active site positively influences
the binding of both molecules. Moreover, the electrostatic
complementarity in both models was a good fit (Fig. 7C).
The activation loop of caspase-8 comprises 12 residues and is
distinct from the  loop that joins the p18 and p12 subunits.
The activation loop is entirely part of the p12 subunit and
comprises one of the Arg residues that normally form the
specificity pocket for the P1 Asp residue of the substrate (other
residues also form this pocket, but Arg-413 is the one that
experiences the largest rearrangement). In the pro-caspase-8
model, the activation loop is positioned in such a way that the
active site is not formed. We postulate that, in the pro-
caspase-8 homodimer or in the pro-caspase-8-FLIPL het-
erodimer, an active site can form by repositioning of the acti-
vation loop, in the absence of any proteolytic processing. This
event is unfavorable in a monomer, but is possible in the
FIG. 8. Stabilization of the func-
tional active site of caspase-8 in the
caspase-8-FLIPL hybrid model. A, the
activation loop of caspase-8 (in red) is in-
teracting with FLIPL. Conformational
changes of caspase-8 induced by FLIPL
allow the formation of the active site of
caspase-8. Top panels show a general
view, whereas a detailed view is shown
below (boxed inset). The side chains of
residues Asn-407 and Asn-408 of
caspase-8 form favorable H-bonds with
the side chains Arg-337 and His-396 of
FLIP, respectively. This type of interac-
tion, which stabilizes the active conforma-
tion of the activation loop, is not present
in the active caspase-8 dimer (65). Pro-
394 and Thr-337 of caspase-8 are the ho-
mologues of His-396 and Arg-337 of FLIP.
B, processing sites in loop  of caspase-8
and FLIP. The pro-caspase-8-FLIP het-
erodimer and the caspase-8 homodimer
are shown with a rotation of 90° compared
with panel A. The Asp residues at the
processing sites (in red) are labeled. Loop
 of caspase-8 is shown in dark brown
and that of FLIP in light brown. Note that
upon cleavage, loop  of caspase-8 folds
over the structure and “locks” the activa-
tion loop (shown in red) in the active con-
formation. The newly generated C termi-
nus at Asp-374 forms a salt bridge with
Lys-224 of the second caspase-8. Arg-243
of FLIP may play a role similar to that of
Lys-224 of caspase-8.
TABLE I
C r.m.s.d. of -caspase-8 and of -caspase-3 during complexation with FLIPL
In the caspase-8-FLIPL heterodimer, a small readjustment of the -subunit of caspase-8 is required to accommodate -FLIPL. Readjustment in
the -subunit of caspase-3 is larger (r.m.s.d. 6 times higher) in comparison to the caspase-3-FLIPL heterodimer.
Complex r.m.s.d. Reference
Å
Pro-caspase-8-FLIPL 0.112 On 53 C; PDB file is 1F9E mol B (67)
Caspase-8-FLIPL 0.135 On 53 C; PDB file is 1F9E mol B (67)
Caspase-3-FLIPL 0.776 On 53 C; PDB file is 1CP3 mol B (35)
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pro-caspase-8 homodimer. However, it appears privileged in
the pro-caspase-8-FLIPL heterodimer, where Asn-407 and Asn-
408 in the activation loop of caspase-8 form hydrogen bonds
with Arg-337 and His-396 of FLIPL, respectively (Fig. 8A).
Pro-caspase-8 can, therefore, transiently exist as an active
protease, in the absence of processing, and this form is stabi-
lized by FLIPL. Active pro-caspase-8 can autoprocess and
cleave itself at Asp-374 (and Asp-384). The loop  appears
long enough to fit without major constraints in the active site of
pro-caspase-8. In addition, the loop  of the neighbor FLIP
could also be processed, and there is no obvious steric hin-
drance for this to occur. Once cleaved after Asp-374, the newly
generated C terminus of the p18 (or p43) subunit of caspase-8
will fold over the structure, passing over the activation loop and
“locking” it in the active conformation (Fig. 8B). In the caspase-
8-caspase-8 homodimer, a salt bridge with Lys-224 of the sec-
ond caspase-8 stabilizes the newly generated C terminus at
Asp-374. This explains how caspase-8 can stay in an active
conformation, even though the activation loop is not stabilized
as efficiently as in the caspase-8-FLIPL heterodimer.
In the active, processed caspase-8 complexed with FLIP,
Arg-243 of FLIPL could play the stabilization role normally
played by Lys-224 of caspase-8.
DISCUSSION
Although the anti-apoptotic function of FLIPL has been well
established in the past, it remained an enigma why FLIPL also
displayed a pro-proapoptotic function upon overexpression. The
current report suggests a possible molecular explanation for
this phenomenon. Our data are compatible with a model in
which FLIPL unscrambles the latent proteolytic activity of
caspase-8 (Fig. 9). In the caspase-8-FLIPL heterodimer,
caspase-8 is not released into the cytoplasm because cleavage
between the DED and the caspase-unit within caspase-8 and
FLIPL does not occur. As a result, the activity of the het-
erodimer remains membrane-restricted and does not result in
apoptosis. Only under conditions of non-physiological overex-
pression of FLIPL where high concentrations of FLIPL accumu-
late in the cytoplasm, FLIPL can activate non-membrane pro-
caspase-8. This causes the activation of caspase-3 or other
pro-apoptotic molecules in the cytoplasm, which subsequently
leads to apoptosis.
The mechanism of caspase-8 activation through FLIPL most
likely resembles the one recently proposed for caspase-9 (46).
There are two fundamental ways in which protease zymogens
are activated, either by limited proteolysis, which removes the
peptide that blocks access to the catalytic site, or by co-factor
binding, which results in the formation of the active site. Acti-
vation by limited processing is required for the downstream
caspases-3 and -7, but proteolysis is not only insufficient but
also unnecessary for caspase-9. Caspase-9 is suggested to be
activated upon dimerization by a “priming” mechanism (46). In
this model, the catalytic machinery of the caspase-9 monomer
is in an inactive conformation. During dimerization, the acti-
vation loop is distorted because of binding to its neighbor and
this motion transmits the activation signal to residues sur-
rounding the cysteine in the active site. Structural and bio-
chemical data indicate that only one of the two catalytic sites of
the dimer is active, whereas the second caspase-9 remains in
its inactive state (46). However, future studies are needed to
demonstrate whether the inactive caspase-9 is also present in
the apoptosome (60).
This dimerization-induced activation model of caspase-9
would satisfactorily explain our data on caspase-8 activation by
FLIPL. In analogy with this model, FLIPL corresponds to the
inactive caspase-9 and induces activation of caspase-8 through
allosteric changes occurring upon activation (Figs. 7 and 9). As
for caspase-9, the interaction between FLIPL and caspase-8 is
mainly formed by interactions between -strands. We propose
that, under physiological concentrations, the interface interac-
tion is too weak to form heterodimers, and FLIPL and caspase-8
remain monomeric in the cytoplasm, whereas heterodimerization
is induced upon recruitment to the DISC. Nevertheless, because
inhibitor binding stabilizes the active form of caspase-8, het-
erodimer formation can be artificially induced by adding zVAD-
fmk as we show in Fig. 4. Again, this is similar to caspase-9,
where inhibitor addition pushes the equilibrium to the dimeric
form (46). Thus, the asymmetric caspase-8-FLIPL heterodimer
has a one-site reactivity, which does not require activation by
cleavage, as evidenced by the capacity of non-processed caspase-8
to react with the biotinylated DEVD-aomk substrate.
The activation of precursor caspase-8 is dependent on the
caspase-like domain of FLIPL. FLIPS, which only contains the
two DEDs, binds to caspase-8 but is unable to activate it. This
short form of FLIPL is therefore predicted to act as an inhibitor
of FLIPL with respect to caspase-8 activation. Indeed, in the
FIG. 9. Proposed mechanism of caspase-8 activation by FLIP.
See “Discussion” text for details.
Activation of Caspase-8 by FLIP 45169
presence of FLIPS, co-recruited caspase-8 is unable to cleave
the DEVD-aomk substrate. In human primary T cells, FLIPS is
induced after 3 days of PHA activation (61), predicting that at
this time point membrane-bound caspase-8 is inhibited. In-
deed, DISC-associated caspase-8 activity inversely correlates
with FLIPS concentration (62).
What is the target protein of membrane-restricted FLIPL-
caspase-8 proteolytic activity? It is reasonable to propose that
the prime substrate is FLIP itself, which is rapidly cleaved
upon stimulation of death receptors. The role of this processing
is not known, but cleavage most likely induces a conforma-
tional change in FLIPL. Cleavage of FLIPL may result in a
weakening of the interaction between the two proteins, possi-
bly resulting in their dissociation. Alternatively, FLIPL cleav-
age may induce the observed ubiquitination of FLIPL and sub-
sequent degradation (63, 64). Yet another possibility is that the
cleavage induces conformational changes that are required for
the reported association of TRAF family members (27). Exper-
iments with non-cleavable FLIPL are currently in progress to
test these hypotheses.
The kinase RIP appears to be a second substrate of the
FLIPL-caspase-8 protease. RIP is known to be crucial for the
activation of the transcription factor NF-B (65). FLIPL-
caspase-8-induced RIP cleavage leads to the generation of a
fragment encompassing the death domain that was previously
shown to act as a dominant negative inhibitor of the NF-B
signaling pathway (58). It can therefore be speculated that RIP
processing through FLIPL-caspase-8 contributes to the down-
regulation of the NF-B signal.
Activation of pro-caspase-8 by FLIPL was recently also re-
ported by Chang and colleagues (66). Using an artificial system
to induce FLIPL dimerization in the cytoplasm, caspase-8 ac-
tivity was found to be induced. Their interpretation of the
results, which are basically in accordance with ours, was that
FLIPL acted as an inhibitor of caspase-8 only at very high
expression levels, whereas at more physiological concentra-
tions, FLIPL was required for the activation of caspase-8 and
hence for apoptosis. However, this model, although interesting,
is difficult to reconcile with the fact that FLIP-deficient cells
are highly sensitive to apoptosis (25).
The activity of caspases is tightly controlled to avoid apo-
ptosis. The acquisition of catalytic activity is therefore sub-
jected to severe controls. It appears that different classes of
caspases have evolved with distinct ways to acquire catalytic
competency. Although downstream caspases are activated by
proteolytic cleavage of the activation loop to generate a rear-
rangement of the active site, at least two upstream caspases
(caspase-9 and caspase-8) seem to have opted for an allosteric
type of activation without need of limited proteolytic cleavage.
This allows activation of the apical caspases in the absence of
any activated upstream protease.
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